$15.84
0.57% today
NYSE, Sep 16, 10:00 pm CET
ISIN
CA98985W1023
Symbol
ZYME

Zymeworks Inc. Stock price

$15.93
+1.57 10.93% 1M
+3.35 26.63% 6M
+1.29 8.81% YTD
+3.42 27.34% 1Y
+10.53 195.00% 3Y
-25.04 61.12% 5Y
+2.93 22.54% 10Y
+2.93 22.54% 20Y
NYSE, Closing price Mon, Sep 15 2025
+0.19 1.21%
ISIN
CA98985W1023
Symbol
ZYME
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$281.4m
Shares outstanding
75.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
73.2%
Return on Equity
-36.2%
ROCE
-22.4%
ROIC
-73.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$122.9m | $158.5m
EBITDA
$-68.7m | $-118.0m
EBIT
$-82.7m | $-68.1m
Net Income
$-73.7m | $-73.5m
Free Cash Flow
$-40.9m
Growth (TTM | estimate)
Revenue
96.0% | 107.8%
EBITDA
38.5% | -8.6%
EBIT
31.4% | 43.2%
Net Income
34.9% | 40.1%
Free Cash Flow
57.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-55.9% | -74.4%
EBIT
-67.3%
Net
-60.0% | -46.3%
Free Cash Flow
-33.3%
More
EPS
$-1.0
FCF per Share
$-0.5
Short interest
11.6%
Employees
273
Rev per Employee
$280.0k
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Zymeworks Inc. forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Zymeworks Inc. forecast:

Buy
80%
Hold
20%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
123 123
96% 96%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 62 62
3% 3%
50%
- Research and Development Expense 144 144
20% 20%
117%
-69 -69
39% 39%
-56%
- Depreciation and Amortization 14 14
57% 57%
11%
EBIT (Operating Income) EBIT -83 -83
31% 31%
-67%
Net Profit -74 -74
35% 35%
-60%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
Seeking Alpha
14 days ago
I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but ZYME is pivoting to a trispecific T-cell engager, ZW209, for improved safety and efficacy. ZW191 and ZW251 ADCs leverage proprietary TOPO1i payloads, targeting large, high-need markets in ovarian ...
Negative
Reuters
14 days ago
Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.
Neutral
GlobeNewsWire
14 days ago
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its decision to voluntarily discontinue clinical devel...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 273
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today